The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Voena, C ^a   Di Giacomo, F ^a   Panizza, E ^a   D'Amico, L ^a   Boccalatte, F E ^a   Pellegrino, E ^a   Todaro, M ^a   Recupero, D ^a   Tabbo F ^a   Ambrogio, C ^a   Martinengo, C ^a   Bonello, L ^a   Pulito, R ^a   Hamm, J ^a   Chiarle, R ^a   Cheng, M ^b   Ruggeri, B ^b   Medico, E ^a,c   Inghirami, G ^a,d  

^a UNIVERSITY OF TURIN   (Italy)

^b CEPHALON INC   (United States)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALK tyrosine kinase; EGR1; HER family; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

AB INITIO CALCULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84880536828     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.7     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
4. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
6. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-377.
7. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18: 382-384.
8. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
9. Jackman DM, Chirieac LR, Janne PA. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med 2005; 26: 342-352.
10. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54: 73-87.
11. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
12. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12: 175-180.
13. Haber DA, Settleman J. Cancer: drivers and passengers. Nature 2007; 446: 145-146.
14. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Janne PA, Wistuba II et al. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009; 15: 5317-5322.
15. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
16. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290.
17. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
19. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-2899.
20. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4: 120ra117.
21. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-1482.
22. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
23. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
24. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
25. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006; 107: 689-697.
26. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
27. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
28. Ott GR, Wells GJ, Thieu TV, Quail MR, Lisko JG, Mesaros EF et al. 2,7-disubstitutedpyrrolo[ 2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J Med Chem 2011; 54: 6328-6341.
29. Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2012; 11: 670-679.
30. Voena C, Panizza E, D'Amico L, Ambrogio C, Martinengo C, Boccalatte FE et al. EML4-ALK signaling is required for the maintenance of neoplastic phenotype of non-small cell lung cancer cells: novel strategy for lung cancer tailored therapies. AACR 101ST Annual Meeting 2010. American Association of Cancer Research (AACR): Washington DC, USA, 2010.
31. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
32. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Clin Cancer Res 2012; 18: 3592-3602.
33. Takezawa K, Okamoto I, Nishio K, Janne PA, Nakagawa K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011; 17: 2140-2148.
34. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-9487.
35. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17: 461-469.
36. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2011; 7: 401-414.
37. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010; 18: 548-551.
38. Sasaki T, Janne PA. New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011; 17: 7213-7218.
39. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 7535-7540.
40. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008; 105: 692-697.
41. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-6060.
42. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010; 70: 1625-1634.
43. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
44. Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010; 29: 2628-2637.
45. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193: 287-292.
46. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 2011; 73: 361-365.
47. Park K, Chung YJ, So H, Kim K, Park J, Oh M et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 2011; 43: 91-100.
48. Kosriwong K, Menheniott TR, Giraud AS, Jearanaikoon P, Sripa B, Limpaiboon T. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. World J Gastroenterol 2011; 17: 1631-1641.